دورية أكاديمية
High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
| العنوان: | High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia. |
|---|---|
| المؤلفون: | Oya S; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Ozawa H; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Morishige S; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.; Department of Medicine, Inuzuka Hospital, Kashima, Saga, Japan., Maehiro Y; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Umeda M; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Takaki Y; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Fukuyama T; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Yamasaki Y; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Nakamura T; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Yamaguchi M; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Aoyama K; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Mouri F; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan., Nagafuji K; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. knagafuji@med.kurume-u.ac.jp. |
| المصدر: | International journal of hematology [Int J Hematol] 2024 Sep; Vol. 120 (3), pp. 297-304. Date of Electronic Publication: 2024 Jul 04. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2008- : Tokyo : Springer Japan Original Publication: Amsterdam : Elsevier Science Publishers, c1991- |
| مواضيع طبية MeSH: | Gemtuzumab*/administration & dosage , Cytarabine*/administration & dosage , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/mortality , Nucleophosmin* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Consolidation Chemotherapy* , Aminoglycosides*/administration & dosage, Humans ; Male ; Middle Aged ; Female ; Aged ; Adult ; Polymorphism, Single Nucleotide ; Sialic Acid Binding Ig-like Lectin 3/genetics ; Nuclear Proteins/genetics ; Mutation ; Treatment Outcome |
| مستخلص: | Previous prospective randomized trials have investigated the efficacy of gemtuzumab ozogamicin in the frontline treatment of acute myeloid leukemia (AML). We evaluated the efficacy of high-dose cytarabine with GO as consolidation therapy in 20 patients with favorable- or intermediate-risk AML in first complete remission. They included six patients with wild-type nucleophosmin (NPM1) core binding factor (CBF), ten with NPM1-mutated non-CBF, and four with wild-type NPM1 non-CBF. The median follow-up for the entire cohort was 62.0 months. The three-year overall survival (OS) and relapse-free survival (RFS) rates were 72.2% and 77.8%, respectively. OS and RFS were significantly higher for NPM1-mutated non-CBF AML than for wild-type NPM1 non-CBF AML (p = 0.001). We also examined the CD33 single-nucleotide polymorphism (SNP) rs12459419, which has been reported to influence the therapeutic efficacy of GO and CD33 expression. The CD33 expression ratio was higher in CD33 SNP C/C than in C/T (83.1% vs. 49.8%, p = 0.035), but 3-year OS and RFS did not differ significantly. These results suggest that consolidation therapy with high-dose cytarabine plus GO is highly effective in transplant-ineligible elderly patients and may be a reasonable treatment, especially for NPM1-mutated AML. (© 2024. Japanese Society of Hematology.) |
| References: | Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84. (PMID: 10.1182/blood.V93.11.367810339474) Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54. (PMID: 10.1200/JCO.2001.19.13.324411432892) Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52. (PMID: 10.1002/cncr.2132616116598) Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60. https://doi.org/10.1182/blood-2013-01-466706 . (PMID: 10.1182/blood-2013-01-466706235917893682338) Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379(9825):1508–16. https://doi.org/10.1016/s0140-6736(12)60485-1 . (PMID: 10.1016/s0140-6736(12)60485-122482940) Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96. https://doi.org/10.1016/s1470-2045(14)70281-5 . (PMID: 10.1016/s1470-2045(14)70281-5250082584137593) Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci. 2011;102(7):1358–65. https://doi.org/10.1111/j.1349-7006.2011.01957.x . (PMID: 10.1111/j.1349-7006.2011.01957.x21585619) Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. (PMID: 10.1182/blood-2016-08-733196278950585291965) Jeon Y, Seo SW, Park S, Park S, Kim SY, Ra EK, et al. Identification of two novel NPM1 mutations in patients with acute myeloid leukemia. Ann Lab Med. 2013;33(1):60–4. (PMID: 10.3343/alm.2013.33.1.6023301224) Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244 . (PMID: 10.1038/bmt.2012.24423208313) Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79. (PMID: 10.1182/blood.V118.21.79.79) Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379(9825):1508–16. https://doi.org/10.1016/s0140-6736(12)60485-1 . (PMID: 10.1016/s0140-6736(12)60485-122482940) Naeem K, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, et al. Significance of blast CD33 expression for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukemia: results from the UK NCRI AML16/17 trials. Blood. 2015;126(23):320. (PMID: 10.1182/blood.V126.23.320.320) Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135(8):542–6. https://doi.org/10.1182/blood.2019003471 . (PMID: 10.1182/blood.201900347131880804) Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09–09 phase III study. J Clin Oncol. 2020;38(6):623–32. https://doi.org/10.1200/jco.19.01406 . (PMID: 10.1200/jco.19.0140631851556) Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10(7):e495–509. https://doi.org/10.1016/s2352-3026(23)00089-3 . (PMID: 10.1016/s2352-3026(23)00089-337187198) De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10):1548. (PMID: 10.3324/haematol.2011.043786217914743186318) Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1 CEBPA and BAALC. Haematologica. 2012;97(2):241–5. https://doi.org/10.3324/haematol.2010.034447 . (PMID: 10.3324/haematol.2010.034447220581963269484) Juliusson G, Jädersten M, Deneberg S, Lehmann S, Möllgård L, Wennström L, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094–101. https://doi.org/10.1182/bloodadvances.2019001335 . (PMID: 10.1182/bloodadvances.2019001335322035827094014) Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674–85. https://doi.org/10.1182/blood.2022016293 . (PMID: 10.1182/blood.20220162933596087110653004) Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, et al. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study. Int J Hematol. 2023;118(1):36–46. https://doi.org/10.1007/s12185-023-03567-1 . (PMID: 10.1007/s12185-023-03567-136853451) Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol. 2016;34(7):747. (PMID: 10.1200/JCO.2015.62.6846267869214872025) Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK, et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood. 2018;131(4):468–71. (PMID: 10.1182/blood-2017-08-80215729229596) Schwarz F, Springer SA, Altheide TK, Varki NM, Gagneux P, Varki A. Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline. Proc Natl Acad Sci. 2016;113(1):74–9. (PMID: 10.1073/pnas.151795111226621708) |
| فهرسة مساهمة: | Keywords: NPM1-mutated AML; Consolidation therapy; Gemtuzumab ozogamicin |
| المشرفين على المادة: | 93NS566KF7 (Gemtuzumab) 04079A1RDZ (Cytarabine) 117896-08-9 (Nucleophosmin) 0 (NPM1 protein, human) 0 (Aminoglycosides) 0 (Sialic Acid Binding Ig-like Lectin 3) 0 (Nuclear Proteins) 0 (CD33 protein, human) |
| تواريخ الأحداث: | Date Created: 20240704 Date Completed: 20240829 Latest Revision: 20240829 |
| رمز التحديث: | 20240830 |
| DOI: | 10.1007/s12185-024-03814-z |
| PMID: | 38963637 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1865-3774 |
|---|---|
| DOI: | 10.1007/s12185-024-03814-z |